Evidence map›Paper›PMID 19194319›Full record

Trial reportJournal of acquired immune deficiency syndromes (1999)2009

Replication capacity in relation to immunologic and virologic outcomes in HIV-1-infected treatment-naive subjects.

Gail Skowron, John G Spritzler, Jodi Weidler, Gregory K Robbins, Victoria A Johnson, Ellen S Chan, David M Asmuth, Rajesh T Gandhi, Yolanda Lie, Michael Bates and 2 more

Erratum issuedAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of acquired immune deficiency syndromes (1999), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Reanalysis of coreceptor tropism in HIV-1-infected adults using a phenotypic assay with enhanced sensitivity.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2011
    Article
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

12 authors.

Gail SkowronDivision of Infectious Diseases, Roger Williams Medical Center, Providence, RI 02908, USA. gail_skowron@brown.edu
John G Spritzler
Jodi Weidler
Gregory K Robbins
Victoria A Johnson
Ellen S Chan
David M Asmuth
Rajesh T Gandhi
Yolanda Lie
Michael Bates
Richard B Pollard
NIH/NIAID ACTG 384 Protocol Team and Monogram Biosciences

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
WOMEN'S HEALTH AGENDAU01AI038858 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI BENSON, CONSTANCE ANN · 1996 to 2008
$157.5M
AIDS Clinical Trials Group NetworkU01AI068636 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI KURITZKES, DANIEL R. · 2006 to 2010
$147.1M
The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ROBERT A. PARKER · 2004 to 2026
$94.4M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Statistical and Data Management Center for the AIDS Clinical Trials GroupU01AI068634 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI HUGHES, MICHAEL DAVID · 2006 to 2010
$71.9M
ZOPOLRESTAT PHARMACOKINETICS IN DIABETICS WITH VARYING RENAL FUNCTIONM01RR000051 · NCRR · UNIVERSITY OF COLORADO DENVER · PI KOSMISKI, LISA A. · 1985 to 2008
$52.6M
Zonisamide in Patients with Neuropathic Pain Associated with Diabetic NeuropathyM01RR000046 · NCRR · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JOY, MELANIE S · 1985 to 2008
$38.5M
ZINC AND CA EDTA THERAPY OF PLUMBISMM01RR000052 · NCRR · JOHNS HOPKINS UNIVERSITY · PI BELCHER, HAROLYN MILLICENT EDITH · 1985 to 2007
$37.3M
VEGF VECTOR TO ISCHEMIC MYOCARDIUM W/DIFFUSE CORONARY DISEASEM01RR000047 · NCRR · WEILL MEDICAL COLL OF CORNELL UNIV · PI MCQUIGGAN, MARGARET M · 1985 to 2007
$36.4M
ZOPOLRESTAT IN SUBJECTS W/ PERIPHERAL SYMMETRICAL DIABETIC POLYNEUROPATHYM01RR000096 · NCRR · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI NOVIK, YELENA · 1985 to 2008
$34.8M
NCRR NIH HHS M01 RR000044NCRR NIH HHS M01 RR000046NCRR NIH HHS M01 RR000047NCRR NIH HHS M01 RR000051NCRR NIH HHS M01 RR000052NCRR NIH HHS M01 RR000096NCRR NIH HHS M01 RR005096NIAID NIH HHS 1P30AI060354NIAID NIH HHS AI46381NIAID NIH HHS K01 AI062435NIAID NIH HHS K01AI062435NIAID NIH HHS P30 AI050410NIAID NIH HHS P30 AI060354NIAID NIH HHS R01 AI066992NIAID NIH HHS R01AI066992NIAID NIH HHS R44 AI050321NIAID NIH HHS R44AI050321NIAID NIH HHS U01 AI025859NIAID NIH HHS U01 AI025868NIAID NIH HHS U01 AI025879NIAID NIH HHS U01 AI025897NIAID NIH HHS U01 AI025903NIAID NIH HHS U01 AI025915NIAID NIH HHS U01 AI025924NIAID NIH HHS U01 AI027658NIAID NIH HHS U01 AI027659NIAID NIH HHS U01 AI027660NIAID NIH HHS U01 AI027661NIAID NIH HHS U01 AI027664NIAID NIH HHS U01 AI027665NIAID NIH HHS U01 AI027666NIAID NIH HHS U01 AI027668NIAID NIH HHS U01 AI027670NIAID NIH HHS U01 AI027673NIAID NIH HHS U01 AI027675NIAID NIH HHS U01 AI032770NIAID NIH HHS U01 AI032775NIAID NIH HHS U01 AI032782NIAID NIH HHS U01 AI032783NIAID NIH HHS U01 AI034832NIAID NIH HHS U01 AI038858NIAID NIH HHS U01 AI039156NIAID NIH HHS U01 AI046381NIAID NIH HHS U01 AI046386NIAID NIH HHS U01 AI068634NIAID NIH HHS U01 AI068636NIAID NIH HHS U01 AI38858NIAID NIH HHS U01 AI68634NIAID NIH HHS U01 AI68636NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI069477NIDDK NIH HHS R01 DK056593
6 · The paper itself

Abstract

objectivesTo evaluate the association between baseline (BL) replication capacity (RC) (RCBL) and immunologic/virologic parameters (at BL and after 48 weeks on therapy) in HIV-1-infected subjects initiating antiretroviral therapy.

methodsRCBL was determined using a modified Monogram PhenoSense HIV drug susceptibility assay on plasma HIV-1 from 321 treatment-naive subjects from AIDS Clinical Trials Group 384. Univariate and multivariable analyses were performed to determine the association of RCBL with BL and on-therapy virologic and immunologic outcomes.

resultsHigher RCBL was associated with lower baseline CD4 (CD4BL) (r = -0.23, P < 0.0001), higher baseline HIV-1 RNA (r = 0.25, P < 0.0001), higher CD4BL activation percent (r = 0.23, P < 0.0001), and lower CD4BL memory count (r = -0.21, P = 0.0002). In a multivariable model, week 48 CD4 increase (DeltaCD448) was associated with lower CD4BL memory count and higher CD4BL-naive percent (P = 0.004, P = 0.015, respectively). The interaction between CD4BL and RCBL was significant (P = 0.018), with a positive association between RCBL and DeltaCD448 in subjects with higher CD4BL and a negative association at lower absCD4BL.

conclusionsAt baseline, higher RC was significantly associated with higher HIV-1 RNA, higher CD4 cell activation, lower CD4 cell count, and lower CD4 memory cell count. These factors may interact, directly or indirectly, to modify the extent to which CD4 recovery occurs in patients starting antiretroviral therapy at different CD4BL counts.

Indexed as

Viral LoadVirus ReplicationAdultAgedCD4 Lymphocyte CountFemaleHIV-1HIV InfectionsHumansMaleMiddle Aged

Identifiers

PMID19194319
PMCPMC3482469

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.